SCHEMBL29754159

SCHEMBL29754159

Cc1cnc(Nc2cnn(C3CC3)c2)nc1-c1ccc(NCC2(C#N)CC2)cc1

nearest known ligand 0.45

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
▸ JAK2 O60674 11/20 0.45
▸ JAK3 P52333 9/20 0.45
▸ JAK1 P23458 9/20 0.45
▸ TYK2 P29597 7/20 0.45
▸ STAT3 P40763 5/20 0.45
▸ ABL1 P00519 1/20 0.44
▸ KDR P35968 1/20 0.44
▸ GSK3B P49841 1/20 0.44
▸ AURKB Q96GD4 1/20 0.44
▸ MAP4K1 Q92918 4/20 0.42
▸ CCNE1 P24864 1/20 0.42
▸ CDK2 P24941 1/20 0.42
▸ MAP3K14 Q99558 1/20 0.41
▸ AXL P30530 1/20 0.41
▸ FLT4 P35916 1/20 0.40
▸ IKBKE Q14164 1/20 0.40
▸ TBK1 Q9UHD2 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL27169581 1.00 JAK2 (0.45) JAK2JAK3JAK1TYK2STAT3
SCHEMBL29754152 0.94 MAP3K14 (0.48) JAK2JAK3JAK1TYK2STAT3
SCHEMBL22545904 0.94 MAP3K14 (0.48) JAK2JAK3JAK1TYK2STAT3
SCHEMBL22097943 0.88 JAK3 (0.52) JAK2JAK3JAK1TYK2STAT3
SCHEMBL27275359 0.85 IGF1R (0.44) JAK2JAK3JAK1CDK2FLT4
SCHEMBL22544652 0.84 JAK2 (0.44) JAK2JAK3JAK1TYK2STAT3
SCHEMBL22544463 0.84 JAK2 (0.43) JAK2JAK3JAK1TYK2STAT3
SCHEMBL29754259 0.84 FLT4 (0.49) JAK2JAK3JAK1KDRAURKB
SCHEMBL27275364 0.84 FLT4 (0.49) JAK2JAK3JAK1KDRAURKB
SCHEMBL27169627 0.83 MAP4K1 (0.46) JAK2JAK3JAK1TYK2STAT3

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20220259182-A1 BENZETHERS AND ANILINES OF PYRAZOLYL-AMINO-PYRIMIDINYL DERIVATIVES, AND COMPOSITIONS AND METHODS THEREOF LYNK PHARMACEUTICALS CO. LTD. (CN) 2022-08-18 — — US claimed
CN-118702683-A Phenyl ethers and anilines of pyrazolyl-amino-pyrimidinyl derivatives, compositions and methods thereof 凌科药业(杭州)有限公司 2024-09-27 — — CN disclosed
US-12024503-B2 Benzethers and anilines of pyrazolyl-amino-pyrimidinyl derivatives, and compositions and methods thereof LYNK PHARMACEUTICALS CO. LTD. (CN) 2024-07-02 — — US disclosed
CN-113993861-B Phenyl ethers and anilines of pyrazolyl-amino-pyrimidinyl derivatives, compositions and methods thereof 凌科药业(杭州)有限公司 2024-05-14 — — CN disclosed
US-20240083882-A1 BENZETHERS AND ANILINES OF PYRAZOLYL-AMINO-PYRIMIDINYL DERIVATIVES, AND COMPOSITIONS AND METHODS THEREOF LYNK PHARMACEUTICALS CO. LTD. (CN) 2024-03-14 — — US disclosed
US-20220259182-A1 BENZETHERS AND ANILINES OF PYRAZOLYL-AMINO-PYRIMIDINYL DERIVATIVES, AND COMPOSITIONS AND METHODS THEREOF LYNK PHARMACEUTICALS CO. LTD. (CN) 2022-08-18 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-12024503-B2 Benzethers and anilines of pyrazolyl-amino-pyrimidinyl derivatives, and compositions and methods thereof JAK3, JAK1, JAK2 JAK2 3/4885JAK3 1/4885JAK1 2/4885
US-20220259182-A1 BENZETHERS AND ANILINES OF PYRAZOLYL-AMINO-PYRIMIDINYL DERIVATIVES, AND COMPOSITIONS AND METHODS THEREOF JAK3, JAK1, JAK2 JAK2 3/4885JAK3 1/4885JAK1 2/4885
US-20240083882-A1 BENZETHERS AND ANILINES OF PYRAZOLYL-AMINO-PYRIMIDINYL DERIVATIVES, AND COMPOSITIONS AND METHODS THEREOF JAK3, JAK1, JAK2 JAK2 3/4885JAK3 1/4885JAK1 2/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback